Structures by: Venugopala K. N.
Total: 54
C14H15FN2O3
C14H15FN2O3
CrystEngComm (2011) 13, 2 591
a=15.829(4)Å b=7.2551(12)Å c=24.285(4)Å
α=90° β=106.972(5)° γ=90°
C15H18N2O4
C15H18N2O4
CrystEngComm (2011) 13, 2 591
a=12.2450(4)Å b=7.4478(2)Å c=16.1914(5)Å
α=90° β=106.676(3)° γ=90°
C14H14FN2O3
C14H14FN2O3
CrystEngComm (2011) 13, 2 591
a=7.5291(6)Å b=9.0289(7)Å c=11.2318(9)Å
α=106.417(1)° β=104.611(1)° γ=100.197(1)°
C14H15FN2O3,C13H12FN2O3,CH3
C14H15FN2O3,C13H12FN2O3,CH3
CrystEngComm (2011) 13, 2 591
a=12.0087(7)Å b=7.3445(4)Å c=29.8816(15)Å
α=90° β=92.941(4)° γ=90°
C14H15ClN2O3
C14H15ClN2O3
CrystEngComm (2011) 13, 2 591
a=12.7632(3)Å b=7.3290(2)Å c=29.7055(10)Å
α=90° β=93.705(2)° γ=90°
C14H15BrN2O3
C14H15BrN2O3
CrystEngComm (2011) 13, 2 591
a=7.5081(6)Å b=8.6307(8)Å c=12.7259(11)Å
α=105.102(8)° β=104.686(7)° γ=100.544(7)°
C15H18N2O4
C15H18N2O4
CrystEngComm (2011) 13, 2 591
a=15.7414(10)Å b=7.3100(4)Å c=26.3147(14)Å
α=90° β=103.377(6)° γ=90°
C15H18N2O3
C15H18N2O3
CrystEngComm (2011) 13, 2 591
a=12.7835(6)Å b=7.3412(3)Å c=29.5499(14)Å
α=90° β=93.462(4)° γ=90°
C15H18N2O5
C15H18N2O5
CrystEngComm (2011) 13, 2 591
a=12.2806(10)Å b=7.4567(6)Å c=17.2659(14)Å
α=90° β=109.584(9)° γ=90°
4-(2,3,4-trimethoxy-phenyl)-6-methyl-2-thioxo-1,2,3,4- tetrahydro-pyrimidine-5-carboxylic acid ethyl ester
C17H22N2O5S
CrystEngComm (2010) 12, 4 1205
a=8.0235(3)Å b=10.6374(5)Å c=11.8171(4)Å
α=84.489(3)° β=74.115(3)° γ=69.045(4)°
4-(2-chloro-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro- pyrimidine-5-carboxylic acid ethyl ester
C14H15ClN2O2S
CrystEngComm (2010) 12, 4 1205
a=11.534(5)Å b=12.540(5)Å c=12.618(5)Å
α=81.012(5)° β=64.177(5)° γ=64.737(5)°
4-(3-Methoxy-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro- pyrimidine-5-carboxylic acid ethyl ester
C15H18N2O3S
CrystEngComm (2010) 12, 4 1205
a=12.286(2)Å b=8.2534(10)Å c=15.956(3)Å
α=90° β=106.98(2)° γ=90°
C16H21N3O2S
C16H21N3O2S
CrystEngComm (2010) 12, 4 1205
a=7.369(3)Å b=9.4420(19)Å c=13.086(3)Å
α=102.79(3)° β=90.557(19)° γ=110.68(2)°
4-(4-Methoxy-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro- pyrimidine-5-carboxylic acid ethyl ester
C15H18N2O3S
CrystEngComm (2010) 12, 4 1205
a=18.239(2)Å b=7.3435(8)Å c=25.197(3)Å
α=90° β=101.957(3)° γ=90°
6-Methyl-2-thioxo-4-p-tolyl-1,2,3,4-tetrahydro-pyrimidine-5- carboxylic acid ethy
C15H18N2O2S
CrystEngComm (2010) 12, 4 1205
a=7.3550(9)Å b=9.4652(12)Å c=12.2073(16)Å
α=74.218(2)° β=88.672(2)° γ=69.844(2)°
4-(4-Fluoro-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro- pyrimidine-5-carboxylic
C14H15FN2O2S
CrystEngComm (2010) 12, 4 1205
a=7.347(2)Å b=9.542(3)Å c=11.327(4)Å
α=71.093(5)° β=88.642(5)° γ=69.792(5)°
4-(3-Chloro-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro- pyrimidine-5-carboxylic
C14H15ClN2O2S
CrystEngComm (2010) 12, 4 1205
a=7.294(3)Å b=10.430(4)Å c=10.634(4)Å
α=107.600(6)° β=90.610(6)° γ=107.820(6)°
Diethyl 2-[4-(4-fluorophenyl)-2-methyl-4-oxobutan-2-yl]malonate
C18H23FO5
Acta Crystallographica Section E (2018) 74, 10 1388-1391
a=7.3066(6)Å b=11.5182(9)Å c=20.2701(17)Å
α=90° β=93.673(2)° γ=90°
Nicotinamide benzoic acid
C7H4ClNO4,C6H6N2O
Acta Crystallographica Section E (2019) 75, 11 1712-1718
a=7.48970(10)Å b=26.3607(5)Å c=7.06230(10)Å
α=90° β=96.3560(10)° γ=90°
[5-(4-Methoxyphenyl)-2-methyl-2<i>H</i>-1,2,3-triazol-4-yl](thiophen-2-yl)methanone
C15H13N3O2S
Acta Crystallographica Section E (2018) 74, 8 1178-1181
a=8.5851(10)Å b=16.8986(19)Å c=9.3455(11)Å
α=90° β=92.465(4)° γ=90°
Benzamide
C7H6INO
Acta Crystallographica Section E (2018) 74, 8 1130-1133
a=5.0531(2)Å b=11.4478(5)Å c=13.2945(5)Å
α=90° β=93.2450(10)° γ=90°
Benzamide
C13H10INO
Acta Crystallographica Section E (2018) 74, 8 1130-1133
a=5.1225(2)Å b=10.4572(4)Å c=12.2167(5)Å
α=66.034(2)° β=78.882(2)° γ=85.760(2)°
Dihydropyrimidine
C13H14N2O4,H2O
Acta Crystallographica Section E (2016) 72, 9 1335-1338
a=10.7527(6)Å b=11.6731(6)Å c=12.4456(7)Å
α=98.236(2)° β=112.3740(10)° γ=108.944(2)°
C20H18ClF3N3O2S,Cl
C20H18ClF3N3O2S,Cl
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 4 681-696
a=7.7005(6)Å b=11.2405(10)Å c=13.7322(12)Å
α=111.249(2)° β=90.907(2)° γ=99.769(2)°
C19H18BrClN3O2,Cl,H2O
C19H18BrClN3O2,Cl,H2O
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 4 681-696
a=14.8702(11)Å b=8.0910(5)Å c=17.7304(13)Å
α=90.00° β=92.203(2)° γ=90.00°
TrifluoroBromoacetophenone
C10H5BrF6O
Acta crystallographica. Section E, Crystallographic communications (2018) 74, Pt 6 868-870
a=14.156(5)Å b=5.0111(16)Å c=15.535(5)Å
α=90° β=104.316(5)° γ=90°
3-(2-Anilino-1,3-thiazol-4-yl)-2H-chromen-2-one
C19H13BrN2O2S
Acta Crystallographica Section E (2006) 62, 7 o2663-o2665
a=10.940(7)Å b=12.172(8)Å c=15.039(10)Å
α=93.025(10)° β=108.484(10)° γ=112.653(9)°
(2<i>Z</i>,3<i>E</i>)-2,3-Bis(2-thienylmethylene)succinic acid methanol hemisolvate
C14H10O4S2,0.5CH4O
Acta Crystallographica Section E (2007) 63, 9 o3722-o3722
a=15.042(7)Å b=13.295(6)Å c=16.219(7)Å
α=90° β=101.792(7)° γ=90°
6-Bromo-3-(dibromoacetyl)-2<i>H</i>-chromen-2-one
C11H5Br3O3
Acta Crystallographica Section E (2007) 63, 12 o4872-o4872
a=7.999(6)Å b=6.794(5)Å c=22.442(17)Å
α=90° β=95.819(12)° γ=90°
3-Dibromoacetyl-2H-chromen-2-one
C11H6Br2O3
Acta Crystallographica Section E (2007) 63, 6 o2826-o2826
a=7.1998(17)Å b=8.969(2)Å c=9.722(2)Å
α=69.094(5)° β=85.974(6)° γ=71.177(4)°
(5S)-1,4-Bis{[(1E)-4-methylbenzylidene]amino}-5-(thien-2-yl)pyrrolidin-2-one
C25H24N4O2S
Acta Crystallographica Section E (2007) 63, 6 o2840-o2840
a=13.777(3)Å b=7.6072(14)Å c=23.431(4)Å
α=90° β=104.167(3)° γ=90°
3-(2-Amino-1,3-thiazol-4-yl)-6-bromo-2<i>H</i>-chromen-2-one
C12H7BrN2O2S
Acta Crystallographica Section E (2009) 65, 12 o3047-o3048
a=7.031(4)Å b=13.804(8)Å c=12.453(7)Å
α=90° β=90.047(9)° γ=90°
3-(2-amino-1,3-thiazol-4-yl)-6-chloro-2<i>H</i>-chromen-2-one
C12H7ClN2O2S
Acta Crystallographica Section E (2009) 65, 12 o3111
a=12.494(8)Å b=7.350(5)Å c=25.013(15)Å
α=90° β=98.156(12)° γ=90°
2-(4-Chloro-3-nitrophenyl)-4-(4-chlorophenyl)-1,3-thiazole
C15H8Cl2N2O2S
Acta Crystallographica Section E (2009) 65, 11 o2611-o2612
a=7.4379(19)Å b=12.305(3)Å c=16.808(4)Å
α=88.596(5)° β=84.131(4)° γ=76.721(5)°
Ethyl 4-(4-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
C14H15ClN2O2S
Acta Crystallographica Section E (2009) 65, 10 o2518
a=7.3420(3)Å b=9.4895(4)Å c=12.0425(5)Å
α=73.823(4)° β=88.512(3)° γ=70.264(4)°
Ethyl 4-(4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate monohydrate
C14H16N2O4,H2O
Acta Crystallographica Section E (2009) 65, 10 o2502
a=5.6859(2)Å b=10.7190(5)Å c=12.1980(5)Å
α=85.267(3)° β=83.990(3)° γ=74.936(4)°
DHMPS
C15H15F3N2O2S
Acta Crystallographica Section E (2011) 67, 7 o1559-o1560
a=7.2682(3)Å b=9.3205(2)Å c=12.4779(3)Å
α=74.199(2)° β=88.092(3)° γ=69.377(3)°
Bromhexine-PTSA salt
C14H21Br2N2,C7H7O3S
Acta Crystallographica Section E (2011) 67, 8 o2032
a=14.008(5)Å b=10.404(5)Å c=17.157(5)Å
α=90° β=110.148(5)° γ=90°
(2-(Benzo[<i>d</i>]thiazol-2yl-methoxy)-5-chlorophenyl)(phenyl)methanone
C21H14ClNO2S
Acta Crystallographica Section E (2012) 68, 11 o3125
a=7.4598(3)Å b=19.3131(8)Å c=24.4002(9)Å
α=90.00° β=90.00° γ=90.00°
Methyl 2,6-diphenyl-1-<i>p</i>-tolyl-4-(<i>p</i>-tolylamino)-1,2,5,6- tetrahydropyridine-3-carboxylate
C33H32N2O2
Acta Crystallographica Section E (2012) 68, 8 o2392-o2393
a=13.3701(11)Å b=6.1744(5)Å c=31.797(2)Å
α=90.00° β=90.381(2)° γ=90.00°
{2-[(1,3-Benzothiazol-2-yl)methoxy]-5-chlorophenyl}(4-chlorophenyl)methanone
C21H13Cl2NO2S
Acta Crystallographica Section E (2013) 69, 7 o1124
a=13.6452(4)Å b=7.47005(19)Å c=18.7286(6)Å
α=90.00° β=105.772(3)° γ=90.00°
{2-[(1,3-Benzothiazol-2-yl)methoxy]-5-fluorophenyl}(4-chlorophenyl)methanone
C21H13ClFNO2S
Acta Crystallographica Section E (2013) 69, 7 o1007-o1008
a=19.7280(6)Å b=7.4755(3)Å c=24.4847(7)Å
α=90° β=90° γ=90°
Ethyl 4-(1,3-benzodioxol-5-yl)-6-methyl-2-sulfanylidene-1,2,3,4- tetrahydropyrimidine-5-carboxylate
C15H16N2O4S
Acta Crystallographica Section E (2011) 67, 11 o3069-o3070
a=12.5102(9)Å b=7.2054(4)Å c=17.0881(12)Å
α=90.00° β=107.178(8)° γ=90.00°
3-(bromoacetyl)-6-fluoro-2H-chromen-2-one
C11H6BrFO3
Acta Crystallographica Section E (2011) 67, 9 o2264
a=4.0590(5)Å b=11.7719(13)Å c=21.608(2)Å
α=90° β=94.318(10)° γ=90°
[2-(1,3-Benzothiazol-2-ylmethoxy)-5-bromophenyl](4-chlorophenyl)methanone
C21H13BrClNO2S
Acta Crystallographica Section E (2013) 69, 1 o70
a=13.7746(3)Å b=7.4918(2)Å c=18.7016(7)Å
α=90° β=106.013(3)° γ=90°
Methyl 4-(4-chlorophenyl)-8-iodo-2-methyl-6-oxo-1,6-dihydro-4<i>H</i>- pyrimido[2,1-<i>b</i>]quinazoline-3-carboxylate
C20H15ClIN3O3
Acta Crystallographica Section E (2013) 69, 1 o123-o124
a=7.3443(15)Å b=10.847(2)Å c=12.475(3)Å
α=106.66(3)° β=103.53(2)° γ=92.79(3)°
Methyl (<i>E</i>)-2-[(3-chloro-4-cyanophenyl)imino]-4-(4-chlorophenyl)- 6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate
C20H16Cl2N4O2
Acta Crystallographica Section E (2012) 68, 10 o2977-o2978
a=11.905(8)Å b=13.729(9)Å c=12.782(8)Å
α=90.00° β=108.366(14)° γ=90.00°
2-(4-Bromoanilino)-6-(4-chlorophenyl)-5-methoxycarbonyl-4-methyl-3,6-dihydropyrimidin-1-ium chloride
C19H18BrClN3O2,Cl
Acta Crystallographica Section E (2013) 69, 4 o518-o519
a=13.2691(15)Å b=11.0965(12)Å c=14.9545(17)Å
α=90° β=114.181(3)° γ=90°
{2-[(1,3-Benzothiazol-2-yl)methoxy]-5-bromophenyl}(phenyl)methanone
C21H14BrNO2S
Acta Crystallographica Section E (2013) 69, 6 o984
a=15.1475(6)Å b=7.6501(3)Å c=15.8339(6)Å
α=90° β=102.105(3)° γ=90°
3-acetylcoumarin
C11H8O3
Crystal Growth & Design (2004) 4, 6 1105
a=11.325(7)Å b=3.987(2)Å c=18.773(11)Å
α=90° β=90.425(10)° γ=90°
3-acetylcoumarin
C11H8O3
Crystal Growth & Design (2004) 4, 6 1105
a=7.496(4)Å b=9.653(6)Å c=12.002(7)Å
α=85.740(9)° β=86.097(9)° γ=81.728(9)°
ANHYDROUS CIPROFLOXACIN
C17H18FN3O3
Crystal Growth & Design (2010) 10, 4 1866
a=8.0622(15)Å b=9.730(2)Å c=10.3214(19)Å
α=99.927(17)° β=104.541(17)° γ=98.073(17)°
Medazolam
C18H13ClFN3
Crystal Growth & Design (2010) 10, 4 1866
a=7.5588(3)Å b=13.6840(5)Å c=15.1242(8)Å
α=90° β=92.497(5)° γ=90°
Anhydrous Ofloxacin
C18H20FN3O4
Crystal Growth & Design (2010) 10, 4 1866
a=30.322(4)Å b=6.8607(8)Å c=16.9199(16)Å
α=90° β=105.271(11)° γ=90°